Aziz Nazha, MD, Thomas Jefferson University, Philadelphia, PA, talks on some of the applications of artificial intelligence (AI) and machine learning in hematological oncology, highlighting the efforts of international collaborations working on these technologies. Dr Nazha explains that AI models can be used to better diagnose patients and differentiate myeloid malignancies, as well as to predict patient survival and response to chemotherapy. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.